- Home
- GLPG vs ADAMI Comparison
GLPG vs ADAMI Comparison
Compare GLPG & ADAMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- ADAMI
- Stock Information
- Founded
- GLPG 1999
- ADAMI N/A
- Country
- GLPG Belgium
- ADAMI United States
- Employees
- GLPG N/A
- ADAMI N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- ADAMI Real Estate Investment Trusts
- Sector
- GLPG Health Care
- ADAMI Real Estate
- Exchange
- GLPG Nasdaq
- ADAMI Nasdaq
- Market Cap
- GLPG 2.1B
- ADAMI 2.3B
- IPO Year
- GLPG 2005
- ADAMI N/A
- Fundamental
- Price
- GLPG $32.02
- ADAMI $25.22
- Analyst Decision
- GLPG Sell
- ADAMI
- Analyst Count
- GLPG 4
- ADAMI 0
- Target Price
- GLPG $25.33
- ADAMI N/A
- AVG Volume (30 Days)
- GLPG 198.2K
- ADAMI N/A
- Earning Date
- GLPG 10-29-2025
- ADAMI N/A
- Dividend Yield
- GLPG N/A
- ADAMI N/A
- EPS Growth
- GLPG N/A
- ADAMI N/A
- EPS
- GLPG N/A
- ADAMI N/A
- Revenue
- GLPG $323,674,692.00
- ADAMI N/A
- Revenue This Year
- GLPG N/A
- ADAMI N/A
- Revenue Next Year
- GLPG N/A
- ADAMI N/A
- P/E Ratio
- GLPG N/A
- ADAMI N/A
- Revenue Growth
- GLPG 5.43
- ADAMI N/A
- 52 Week Low
- GLPG $22.36
- ADAMI N/A
- 52 Week High
- GLPG $33.86
- ADAMI N/A
- Technical
- Relative Strength Index (RSI)
- GLPG 49.28
- ADAMI N/A
- Support Level
- GLPG $30.88
- ADAMI N/A
- Resistance Level
- GLPG $33.63
- ADAMI N/A
- Average True Range (ATR)
- GLPG 0.69
- ADAMI 0.00
- MACD
- GLPG -0.02
- ADAMI 0.00
- Stochastic Oscillator
- GLPG 41.45
- ADAMI 0.00
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.